Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate by Korompis, M, De Voss, CJ, Li, S, Richard, A, Almujri, SS, Ateere, A, Frank, G, Lemoine, C, McShane, H, Stylianou, E

A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults by Fredsgaard-Jones, T, Harris, SA, Morrison, H, Ateere, A, Nassanga, B, Ramon, RL, Mitton, C, Fletcher, E, Decker, J, Preston-Jones, H, Jackson, S, Mawer, A, Satti, I, Barer, M, Hinks, T, Bettinson, H, McShane, H

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response by Drennan, PG, Provine, NM, Harris, SA, Otter, A, Hollett, J, Cooper, C, De Maeyer, RPH, Nassanga, B, Ateere, A, Pudjohartono, MF, Peng, Y, Chen, J-L, Jones, S, Fadzillah, NHM, Grifoni, A, Sette, A, Satti, I, Murray, SM, Rowe, C, Mandal, S, Hallis, B, Klenerman, P, Dong, T, Richards, D, Fullerton, J, McShane, H, Coles, M

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 contro... by Jackson, S, Marshall, JL, Mawer, A, Lopez-Ramon, R, Harris, SA, Satti, I, Hughes, E, Preston-Jones, H, Cabrera Puig, I, Longet, S, Tipton, T, Laidlaw, S, Doherty, RP, Morrison, H, Mitchell, R, Tanner, R, Ateere, A, Stylianou, E, Wu, M-S, Fredsgaard-Jones, TPW, Breuer, J, Rapeport, G, Ferreira, VM, Gleeson, F, Pollard, AJ, Carroll, M, Catchpole, A, Chiu, C, McShane, H, Alparaque, M, Anid, L, Barnes, E, Benamore, R, Bharti, N, Patel, B, Burns, A, Byard, N, Conway, O, Cooper, C, Crowther, C, Dunachie, SJ, Johnstone, T, Jose, J, Luciw, M, Mujadidi, Y, Nehiweze, A, Nyamunda, S, Orobiyi-Rieba, M, Parvelikudy, B, Platt, A